Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayGabapentin and Opioids; Alzheimer’s Drug Decision Nears; Neurology Education in 2035

This neurology news roundup from MedPage Today includes four highlights of note: First, a JAMA Internal Medicine article pointing out that gabapentin will not solve the opioid crisis in the US. Second, ublituximab, approved for relapsing MS at the end of December, has been included in the Institute for Clinical and Economic Review’s report on comparative effectiveness. Third, the same organization says that the newly approved Alzheimer’s drug lecanemab will need to be priced below $21,000 per year to be cost effective. And finally, a link to Neurology‘s crystal ball view into neurology education in the coming decade.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form